• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A nutritional composition comprising synergistic functional carbohydrates for the prevention or treatment of infection by pathogenic bacteria and / or for promoting intestinal flora balance and promoting health. The carbohydrate has a synergistic activity against intestinal bifidobacterial promotion. In addition, a method for producing the composition; The use of said composition in the prevention or treatment of infection by pathogenic bacteria and / or in the manufacture of functional foods or drugs for promoting intestinal flora balance and health promotion; And a method for preventing or treating infection by pathogenic bacteria, and / or a method for promoting intestinal flora and balance and health, comprising administering an effective amount of the composition.
    公开号:KR20030041962A
    申请号:KR10-2003-7001016
    申请日:2001-07-17
    公开日:2003-05-27
    发明作者:로샤플로랑스；발레브르올리비에；얀알프레드
    申请人:소시에떼 데 프로듀이 네슬레 소시에떼아노님；
    IPC主号:
    专利说明:

    Nutritional Composition {NUTRITIONAL COMPOSITION}
    [2] Within the context of this specification, the term "comprising" means "including, among other things," and is not to be considered as "comprising alone."
    [3] Within the context of this specification, "side effect" refers to unwanted side effects that often occur after consumption of fiber. These side effects include, for example, flatulence, swelling and intestinal pain.
    [4] It has been suggested that there are health benefits associated with the growth of intestinal bifidobacteria. These beneficial effects include increased defense against pathogenic bacteria, stimulation of the immune system, and health benefits associated with the production of short chain fatty acids (SCFAs), as well as reduced abdominal sensation. All of these affect gut flora balance and gut health.
    [5] It is known that infection with pathogenic bacteria can be harmful to health. Examples of this bacterium include Clostridium perfringens, C. difficile, Salmonella and other enteropathogens.
    [6] In the past, infections with these harmful bacteria have progressed until they have to be treated with antibiotics. Antibiotics have a good effect on harmful bacteria, but there is a problem that can kill a group of intestinal bacteria that are harmless and help digestion of food. The bacterial population is often said to be "friendly."
    [7] Therefore, in order to promote intestinal flora total balance and health, there are compositions that can prevent or combat infection by pathogenic bacteria, promote defense against pathogenic bacteria, stimulate the immune system and / or increase short-chain fatty acid production. It is necessary.
    [1] The present invention provides a nutritional composition comprising synergistic functional carbohydrates for the prevention or treatment of pathogenic bacterial infections and / or for promoting intestinal flora balance and health; A method of making the composition; The use of said composition in the prevention or treatment of pathogenic bacterial infections, and / or in the manufacture of functional foods or pharmaceuticals for intestinal flora balance and health promotion; And a method for preventing or treating a pathogenic bacterial infection, and / or a method for balancing intestinal flora and health, comprising administering an effective amount of the composition.
    [8] The present invention solves the problems described above.
    [9] Obviously, it has now been found that certain functional carbohydrates can have a synergistic effect on the growth of in vivo and in vivo bifidobacterial populations.
    [10] As a result, in a first aspect of the present invention, the present invention provides a nutritional composition for the prevention or treatment of infection by pathogenic bacteria, and / or for promoting intestinal flora balance and health, which includes inulin or fructooligosaccharide (FOS). Two or more synergistic functional carbohydrates comprising a first carbohydrate selected from the group consisting of and a second carbohydrate selected from the group consisting of xylooligosaccharides (XOS), acacia gum and indigestible starch. It provides a nutritional composition comprising. Carbohydrates are available commercially or more simply by using natural sources such as chicory as the source of inulin.
    [11] In a second aspect, the present invention provides a process for the preparation of the composition comprising combining the required amounts of the corresponding components.
    [12] In a third aspect, the present invention provides the use of a composition according to an embodiment of the present invention in the prevention or treatment of infection by pathogenic bacteria and / or in the preparation of a functional food or drug for promoting intestinal flora balance and health promotion. do.
    [13] In a fourth aspect, the present invention provides the use of a composition according to an embodiment of the present invention for the production of a functional food or drug comprising fiber, while avoiding the side effects of fiber consumption.
    [14] In a fifth aspect, the present invention provides the use of a composition according to an embodiment of the present invention for the manufacture of a functional food or drug for the prevention or treatment of Irritable Bowel Syndrome (IBS).
    [15] In a sixth aspect, the present invention provides a method of treating infection by a pathogenic bacterium, and / or a method for promoting balance and health of the intestinal flora, comprising administering an effective amount of a composition according to an embodiment of the invention.
    [16] In a seventh aspect, the present invention provides a method for reducing the side effects of fiber consumption, comprising administering fiber in the form of a composition according to the present invention.
    [17] In another aspect, the present invention provides a method for reducing irritable bowel syndrome (IBS) comprising administering an effective amount of a composition according to the present invention.
    [18] Preferably, the embodiment of the composition according to the present invention comprises fructooligosaccharide and carbohydrate selected from the group consisting of xyloligosaccharide and acacia gum. More preferably, fructooligosaccharide and acacia gum are included.
    [19] Preferably, an embodiment of the composition according to the present invention comprises about 1 to about 20 g of the first carbohydrate, and about 0.1 to about 20 g of the second carbohydrate. More preferably, for infants, from about 1 to about 3 g of a first carbohydrate, and from 0.2 to about 3 g of a second carbohydrate. Most preferably, for adults, about 2 to about 5 g of the first carbohydrate, and about 2 to about 5 g of the second carbohydrate. It is clear that there are no specific restrictions except those that can be consumed reasonably and prices. This predetermined amount corresponds to the daily dose, which can be divided several times within one day.
    [20] Preferably, in an embodiment of the present composition, the weight ratio of first carbohydrate to second carbohydrate is 1-20: 0.1-20. More preferably, it is 0.05-10: 1, still more preferably 0.1-10: 1.
    [21] Preferably, the implementation of the composition is for human consumption and / or administration. Preferably, alternative embodiments are made for the consumption of companion animals.
    [22] It is an advantage of the present invention to provide a composition which can be provided as a functional food, and thus requires no special administration.
    [23] Another advantage of the present invention is that it does not adversely affect intestinal bacteria that are not harmful or does not kill intestinal friendly bacteria.
    [24] Another advantage of the present invention is to reduce the intestinal required daily carbohydrate, to obtain stimulation of intestinal bifidobacteria, and to promote the associated health benefits. Benefits from this reduction include the reduction of side effects (abdominal disorders) induced by the ingestion of some fermentable carbohydrates, and in some cases cost savings.
    [25] Another advantage of the present invention is to provide a composition of carbohydrates having carbohydrate chains of various lengths. It offers the advantage of controlling fermentation through the colon through which the composition passes.
    [26] Additional features and advantages of the present invention are described in the description of the presently preferred embodiments described below with reference to the drawings in which FIG. 1 shows the effect of various carbohydrates or combinations thereof on human fecal fidobacteria. Will be obvious.
    [27] In accordance with the present invention, the use of certain non-digestible carbohydrates (fibrous or fibrous materials) in vivo and ex vivo can specifically stimulate intestinal bifidobacteria or other lactic acid bacteria. In humans and animals, the Bifidobacteria populations are not the same as individuals and often include several different species of Bifidobacteria.
    [28] The bifidobacterial enzymes involved in the fermentation of an embodiment of the composition according to the invention are not identical and differ depending on the physicochemical structure of the carbohydrates. In addition, Bifidobacteria are not similar in terms of enzyme performance, so the ability to ferment one or another fiber is not the same for each bacteria.
    [29] Thus, a composition according to the invention comprising a mixture of two or more carbohydrates promotes the growth of more bifidobacterial species than a single carbohydrate. Surprisingly, there is a synergistic effect between carbohydrates on the stimulation of Bifidobacteria and their health benefits (examples of carbohydrates include fructo-oligosaccharides, galacto-oligosaccharides, soybean gum, starch, starch). ).
    [30] Additional features of the compositions according to the invention are shown below. Comparative data showing the results in human studies of using fructo-oligosaccharides and acacia gum or xylo-oligosaccharides are shown in the Examples. The data demonstrate that the increase in Bifidobacteria is greater when using a synergistic mixture of carbohydrates than when using a single carbohydrate. These examples are shown below.
    [31] In one embodiment, the nutritional composition preferably comprises a protein source. Dietary proteins are preferred as protein sources. The dietary protein may be any suitable dietary protein, for example animal protein (such as milk protein, meat protein or egg protein); Vegetable proteins (eg, soy protein, wheat protein, rice protein and pea protein); Mixtures of free amino acids; Or combinations thereof. Particular preference is given to milk proteins, such as casein, whey proteins and soy proteins.
    [32] The composition may also include carbohydrate and / or fat sources.
    [33] If the nutritional formula comprises a fat source, the fat source preferably provides about 5 to about 55%, for example about 20 to about 50%, of the energy of the nutritional formula. The lipids that make up the fat source can be any suitable fat or fat mixture. Vegetable fats such as soy milk, palm oil, coconut oil, safflower oil, sunflower oil, corn oil, canola oil, lecithin and the like are particularly suitable. Animal fats such as dairy fats may also be added if desired.
    [34] Additional carbohydrate sources may be added to the nutritional composition. It provides about 40 to about 80% of the energy of the nutritional composition. Any suitable carbohydrate can be used, such as sucrose, lactose, glucose, fructose, corn syrup solids, maltodextrin or mixtures thereof.
    [35] Additional dietary fibers may also be added if desired. When added, it accounts for about 5% or less of the energy of the nutritional composition. Dietary fiber may originate in any suitable source, including, for example, soybeans, peas, oats, pectin, guar gum, gum arabic, fructooligosaccharides or mixtures thereof.
    [36] Appropriate vitamins and minerals may be included in the nutritional composition in amounts that may meet appropriate guidelines.
    [37] One or more food grade emulsifiers, for example diacetyl tartaric acid esters of mono- and diglycerides, lecithin and mono- or diglycerides or mixtures thereof, may be included in the nutritional composition if desired. Similarly suitable salts and / or stabilizers may be included.
    [38] For example, nutritional compositions in the form of powders, concentrates or ready-to-drink beverages are preferably enteric. If a powdered nutritional formulation is to be prepared, the homogenized mixture is transferred to a suitable drying device, such as a spray dryer or a freeze dryer, to convert to a powder.
    [39] Alternatively, the general food may be made of many implementations of the composition. For example, fermented milk, yogurt, fresh cheese, rennet milk, candy bars, breakfast cereal flakes or bars, drinks, emulsion powders, legume products, non-fermented fermented products or nutritional supplements for clinical nutrition, infants or infants There is a dragon food. Thus, the amount of the composition added is preferably about 0.01% by weight or more.
    [40] Embodiments of the present compositions may be included in the confectionery, for example, an item of sweet or sweetened beverage.
    [41] The following examples are for illustrative purposes only and should never be considered as limiting the subject matter of the present application. Percentages and parts are by weight unless otherwise indicated.
    [42] Example 1: Nutritional Composition.
    [43] The trials consisted of three groups of 29 volunteers each:
    [44] FOS: 6 g of Raphtilose P95N per day for 6 weeks
    [45] XOS: 0.4 g xylo-oligo P95 per day for 6 weeks
    [46] XOS FOS: 4 g of FOS per day for 6 weeks and 0.2 g of XOS per day
    [47] Six weeks before treatment, a three week wash-out period was observed. The participants then went through an additional five week follow-up process after treatment. During the wash-out and palu-up periods, participants received placebos.
    [48] During the full test period, subjects banned ingestion of fermented yogurt and bifidus containing products.
    [49] In general, subjects showed an increase in the Bifidobacterial coefficient, especially those with low initial values. In addition, an increase in the mean and median values was also calculated. Formal statistical analysis showed the following results:
    [50] FOS (log 10 cfu / g)Start1 week laterDifferencep-value Average (t-test)8.419.02+0.610.019 XOS (log 10 cfu / g)Average (t-test)7.438.11+0.680.042 XOS FOS (log 10 cfu / g)Average (t-test)7.398.85+1.45<0.001
    [51] Differences in Bifidobacterial coefficient between the start of treatment and one week after treatment.
    [52] The results in the table clearly demonstrate that FOS and XOS FOS significantly increase the mean Bifidobacterial coefficient. This is also the case for XOS, but less. The increase obtained with mixed XOS FOS is higher synergistically.
    [53] Example 2:
    [54] According to the protocol, a trial was designed to compare three groups of 31 subjects each.
    [55] FOS: 200 ml skim milk powder with 6 g of Raphthylos P95 ™ per serving
    [56] Fiber gum: 200 ml skim milk powder with 6 g of fiber gum AS IRX
    [57] FOS + Fibergum: 200 ml skim milk powder with Raphtylos P95 (per serving, 3 g) and Fibergum TX (per serving, 3 g).
    [58] After initiation of the study, fecal samples were tested on days 7, 21, 28, 49 and 71. Intervention time is 21 days to 49 days. Particular attention is paid to changes from day 21 to day 28.
    [59] According to the protocol, an increase in bifidobacteria of +1.35 log 10 cfu / g feces after one week of treatment is expected in the FOS + fiber gum group.
    [60] Each change in the FOS + fiber gum group from day 21 to day 28 is summarized as follows:
    [61] Minimum 1 Qu. Average 3 Qu. Max
    [62] -0.330.071.3841.426.73
    [63] The differences were analyzed in two ways, first in quantitative terms and then in qualitative terms.
    [64] Using a robust position estimator, for example an M-estimation using the Turkish Bissquare function, an average of 0.307 log 10 cfu / g feces, close to the median, was obtained. The 95% confidence interval was calculated as 1000 bootstraps (this is why the M-estimated amount is preferred over the median in this case). This indicated 0.14 and 1.00 (interval not including the value 0) as thresholds, indicating that the increase is statistically significant.
    [65] Responders were calculated: We selected based on an increase of +0.5 log 10 cfu / g feces or more. This was observed in 13 of 29 subjects, representing 44.8% of volunteers. The 95% -confidence interval for this fraction was 27-64%. More than 27% of the subjects respond to the diet provided, which is about 64%.
    [66] Using both approaches, significant results were obtained.
    [67] For the fiber gum group, the following differences were obtained:
    [68] Minimum 1 Qu. Average 3 Qu. Max
    [69] -6.2600.66780.8756.6
    [70] Here, the difference between the median value and the mean value was smaller, and the t-test was appropriate.
    [71] Mean increase is at the limit of statistical significance (p-value = 0.09, 95%-CI: [-0.11, 1.45]).
    [72] Finally, for the FOS group the differences were distributed as follows:
    [73] Minimum 1 Qu. Average 3 Qu. Max
    [74] -4.040.06250.28530.6554.31
    [75] Example 3:
    [76] One hundred volunteers were randomly assigned to four dietary groups, but sorted by the amount, sex, age, and average fraction of fiber in the daily diet, of their original intestinal bleed prior to testing.
    [77] -Control group: reference product
    [78] -FOS + gum: 3 g of Raphthylos ™ and 3.56 g of fiber gum per serving
    [79] Starch: 10 g of indigestible starch per serving
    [80] -Formulation: 3 g of Raphtyloso® + 3.56 g of fiber gum + 10 g of indigestible starch per serving
    [81] The primary analysis was to calculate the effect on the amount of bifidobacteria in the feces. The count of other microorganisms was also analyzed. After another analysis was performed to determine changes in abdominal sensations (flatulence, defecation and recovery) assessed by volunteers, several short-chain fatty acids measured in feces were analyzed.
    [82] The 100 volunteers were divided into four groups:
    [83] Control group: 13 subjects (8 females, 5 males)
    [84] FOS + Sword: 29 subjects (19 females, 10 males)
    [85] Starch: 29 subjects (19 female, 10 male)
    [86] Combination: 29 subjects (19 females, 10 males)
    [87] The average amount, age and fraction of fiber of their Bifidobacteria were similar. There was only one subject (group "FOS + sword") that was obviously not compliant, and the data was omitted.
    [88] After 4 weeks of treatment, 50% of the subjects show an increase in bifidobacteria above +0.5 log 10 cfu / g feces.
    [89] During the “day 20 to day 48” period, the following results of log 10 cfu bifidobacteria / g feces (p) in the number of people (n) are obtained. In (n), the number having 0.5 log 10 cfu / g or more is shown in the first column (+0.5).
    [90] Bifidobacteria: Day 40-Day 20
    [91] +0.5npLower limitUpper limit Control31323.16.254.0 FOS + Sword92733.317.254.0 Starch72725.911.946.6 Formulation 13 27 48.1 29.2 67.6
    [92] In the table, we can see that 3 of 13 subjects in the control group had an increase of at least 0.5 log 10 cfu / g feces. This represents 23.1% and 95% -confidence interval (CI) ranged from 6.2% to 54.0%. For the blend, the fraction was close to 50% and the lower limit of 95% -CI was greater than 25%. Clearly, after 4 weeks of formulation consumption, there was a significant effect.
    [93] After 1 week, the following results were obtained:
    [94] Bifidobacteria: Day 27-Day 20
    [95] +0.5npLower limitUpper limit Control51338.515.167.7 FOS + Sword 12 28 42.9 25.0 62.6 Starch92832.116.652.4 Formulation112937.921.357.6
    [96] Here, the effect of FOS + gum was significant and the formulation is at the limit of statistical significance.
    [97] The change in the amount of Bifidobacteria was checked to assess whether it was related to the average fraction of fiber ingested for the subject 1 to 4 weeks after treatment.
    [98] Similar experiments were performed to determine the amount of lactobacillus, bacteroides, enterobacteria and clostridium per fingens. Surprisingly, it has been found that the number of bacteria has not changed significantly for different diets. This demonstrates the surprising result that the embodiment of the present invention has the effect of promoting specifically Bifidobacteria. These results have a positive effect on digestion, combat infection by pathogenic bacteria, stimulate the immune system, increase short chain fatty acid production, and consequently promote intestinal flora total balance and health.
    [99] It is to be understood that various changes and modifications to the presently preferred implementations described herein will be apparent to those skilled in the art. Such changes and modifications may be made without departing from the spirit and scope of the present invention and without diminishing its benefit. Therefore, it is intended that such changes and modifications be protected by the appended claims.
    权利要求:
    Claims (14)
    [1" claim-type="Currently amended] A nutritional composition for the prevention or treatment of infection by pathogenic bacteria, and / or for intestinal flora total balance and health promotion, the first carbohydrate selected from the group consisting of inulin or fructooligosaccharide (FOS), and xyloligo A nutritional composition comprising two or more synergistic functional carbohydrates comprising a second carbohydrate selected from the group consisting of saccharides (XOS), acacia gum and indigestible starch.
    [2" claim-type="Currently amended] The nutritional composition of claim 1 comprising chicory as a source of inulin.
    [3" claim-type="Currently amended] The composition of claim 1 or 2 comprising fructooligosaccharides and carbohydrates selected from the group consisting of xyloligosaccharides and acacia gums.
    [4" claim-type="Currently amended] The composition of claim 1 or 2 comprising fructooligosaccharide and acacia gum.
    [5" claim-type="Currently amended] The composition according to any one of claims 1 to 4, wherein the weight ratio of the first functional carbohydrate to the second functional carbohydrate is 1-20: 0.1-20.
    [6" claim-type="Currently amended] The composition according to any one of claims 1 to 5, which is formulated for consumption and / or administration of humans or companion animals.
    [7" claim-type="Currently amended] 7. A composition according to any one of claims 1 to 6 comprising a third carbohydrate which is an indigestible starch.
    [8" claim-type="Currently amended] A method for preparing a composition according to any one of claims 1 to 7, which comprises combining the required amounts of the corresponding components.
    [9" claim-type="Currently amended] Use of a composition according to any one of claims 1 to 7 in the prevention or treatment of infection by pathogenic bacteria and / or in the manufacture of a functional food or drug for promoting intestinal flora balance and health promotion.
    [10" claim-type="Currently amended] Use of a composition according to any one of claims 1 to 7 for the manufacture of a functional food or drug comprising fiber, while avoiding the side effects of fiber consumption.
    [11" claim-type="Currently amended] Use of a composition according to any one of claims 1 to 7 for the manufacture of a functional food or drug for the prophylaxis or treatment of irritable bowel syndrome (IBS).
    [12" claim-type="Currently amended] A method for the treatment of infection by pathogenic bacteria, and / or intestinal flora total balance and health promotion method comprising administering an effective amount of the composition according to any one of claims 1 to 7.
    [13" claim-type="Currently amended] A method for reducing the side effects of fiber consumption, comprising administering fiber in the form of a composition according to claim 1.
    [14" claim-type="Currently amended] A method of reducing irritable bowel syndrome (IBS) comprising administering an effective amount of a composition according to claim 1.
    类似技术:
    公开号 | 公开日 | 专利标题
    US20200078385A1|2020-03-12|Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
    Richman et al.2013|evidence‐based dietary advice for patients with inflammatory bowel disease
    JP6205003B2|2017-09-27|Nutritional composition for promoting gut microbiota balance and health
    JP6285108B2|2018-02-28|Probiotics in pre-operative and / or post-operative environments
    US20180110253A1|2018-04-26|Oligosaccharide mixture and food product comprising same
    US9737089B2|2017-08-22|Milk-based nutritional compositions containing lactoferrin and uses thereof
    Aluko2012|Functional foods and nutraceuticals
    AU2015341572B9|2020-05-07|Composition
    Valdemiro Carlos2011|The importance of prebiotics in functional foods and clinical practice
    AU2012260945B2|2016-03-03|Milk oligosaccharide-galactooligosaccharide composition for infant formula containing the soluble oligosaccharide fraction present in milk, and having a low level of monosaccharides, and a process to produce the composition
    US9609888B2|2017-04-04|Nutritional compositions containing synergistic combination and uses thereof
    Heinrichs et al.2003|Effects of mannan oligosaccharide or antibiotics in neonatal diets on health and growth of dairy calves
    US8580295B2|2013-11-12|Carbohydrates mixture
    AU2006340316B2|2013-03-28|High-calorie nutritional supplement
    Vandenplas2002|Oligosaccharides in infant formula
    ES2604319T3|2017-03-06|Nutritive composition to promote healthy growth and development
    EP1383514B1|2007-01-03|Use of a composition comprising a prebiotic for decreasing inflammatory process and abnormal activation of non-specific immune parameters
    CN101188947B|2012-07-04|Use of polydextrose for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
    DE60210603T2|2007-04-05|Dual brazing system and its use
    EP2608681B1|2015-09-16|Nutritional products having improved organoleptic properties
    ES2621936T3|2017-07-05|Method for preparing whey protein compositions
    AU709155B2|1999-08-19|Compositions and methods for human gastrointestinal health
    CA2542652C|2014-05-13|Nutritional composition against side effects of chemotherapy or radiotherapy
    DE60122570T3|2015-05-21|Food composition for immune disease
    EP1313376B1|2005-12-21|Nutritional composition
    同族专利:
    公开号 | 公开日
    JP4955896B2|2012-06-20|
    CN100349575C|2007-11-21|
    NO20030316D0|2003-01-21|
    DE60143356D1|2010-12-09|
    EP2255815B1|2017-10-25|
    BG107473A|2004-07-30|
    CA2416990C|2010-09-14|
    EP2255815A3|2012-07-11|
    EP2255815A2|2010-12-01|
    US7141554B2|2006-11-28|
    MXPA03000742A|2003-09-25|
    ES2355754T3|2011-03-30|
    CA2416990A1|2002-01-31|
    ES2650122T3|2018-01-17|
    EP1305036A2|2003-05-02|
    EP2204176A3|2010-07-14|
    US20030166610A1|2003-09-04|
    EP1175905A1|2002-01-30|
    EP2204176A2|2010-07-07|
    ZA200301401B|2004-05-21|
    WO2002007533A2|2002-01-31|
    US20050053641A1|2005-03-10|
    PT1305036E|2011-01-28|
    IL153989A|2005-08-31|
    CN1466459A|2004-01-07|
    HU0303728A2|2004-03-29|
    JP2004504332A|2004-02-12|
    DK1305036T3|2011-02-07|
    PL366049A1|2005-01-24|
    NO20030316L|2003-03-14|
    WO2002007533A3|2002-04-11|
    EP1305036B1|2010-10-27|
    AT485827T|2010-11-15|
    BR0112685A|2003-06-24|
    AU8968001A|2002-02-05|
    HU0303728A3|2004-12-28|
    IL153989D0|2003-07-31|
    BRPI0112685B1|2020-04-07|
    CZ2003535A3|2003-09-17|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2000-07-24|Priority to EP00115850A
    2000-07-24|Priority to EP00115850.0
    2001-07-17|Application filed by 소시에떼 데 프로듀이 네슬레 소시에떼아노님
    2001-07-17|Priority to PCT/EP2001/008283
    2003-05-27|Publication of KR20030041962A
    优先权:
    申请号 | 申请日 | 专利标题
    EP00115850A|EP1175905A1|2000-07-24|2000-07-24|Nutritional Composition|
    EP00115850.0|2000-07-24|
    PCT/EP2001/008283|WO2002007533A2|2000-07-24|2001-07-17|Nutritional composition|
    [返回顶部]